

INTERIM REPORT
for I-IX 2025
Medika d.d. Zagreb

October 2025

Management interim report

Comment on the business results for the third quarter of 2025

Medika d.d. („Company“) has realised total revenue in the first nine months of 2025 in amount of EUR 696.8 million which is by 15.89% higher comparing to the same period of previous year. The increase in total revenues is a result of market growth and increased sales.

Net sales revenues which amount to EUR 683.0 million for the first nine months of 2025 are by 14 % higher compared to the same period of previous year.

Share of sales revenues in the total revenue is 98.02% while in the same period of previous year it was 99.03%. Other operating revenues which amount to EUR 4.5 million are higher by 26.09% comparing to the same period of previous year. Share of other operating revenues in total revenue is 0.64% in the first nine months of 2025, while in the same period of previous year amounted to 0.59%.

Out of the total sales revenues, in the first nine months of 2025, 99.01% revenues are generated on domestic market, while 0.99% is generated on the foreign market. In the first nine months of 2024, 99.31% revenues were generated on domestic market, while 0.69% were generated on the foreign market.

Material expenses amount to EUR 657.7 million and are by 15.49% higher compared to the same period of previous year, which is slightly higher than the increase of sales. The share of material expenses in the operating expenses amount to 97.36%, while in the same period of previous year amounted to 97.13%.

Employee expenses are higher by 14.22% compared to the same period of previous year. Their share in the total expenses amounts to 1.49% which decreased by 0.02 percentage points compared to the same period of the previous year. This increase of employee expenses, compared to the same period of the previous year, was affected by the higher average number of employees, salary increases for employees during 2024 and 2025 and employment of foreign workers.

Financial expenses have increased compared to the same period of previous year by 2.56%. Their share in total expenses is 0.2%. This increase was influenced by higher average indebtedness in the first nine months of 2025 compared to the same period of the previous year.

Interest income amounted to EUR 9.3 million, which is higher by EUR 7.0 million compared to the same period last year.

Gross margin in the first nine months of 2024 amounted to 4.82%, while in the first nine months of 2025 amounts to 4.52%, which is a decrease by 0.3 percentage points.

Gross profit (profit before taxation) amounts to EUR 20.0 million and is 45.45% higher compared to the same period of the previous year.

Operative earnings amount to EUR 12.0 million and are by EUR 763 thousand or 5.99% lower comparing to the same period of previous year.

Realised net profit amounts to EUR 16.2 million.

Transactions with the related parties in the first nine months of 2025 generated total net revenues in amount of EUR 59.7 million, which is 6.72% higher compared to generated revenue in the same period of previous year when it amounted to EUR 56.0 million. The increase is mostly a result of increased sales in Prima Pharme Group.

Trade goods purchased from related parties amounts to EUR 46.7 million, while in the same period of previous year amounted to EUR 43.7 million, which is an increase of EUR 3.0 million, or 6.96%.

Total assets amount to EUR 551.8 million which is by 26.24% higher comparing to the beginning of the year.

Long term asset is 14.35% higher comparing to the beginning of the year. Non-current intangible assets amount to EUR 14.3 million which is by 59.53% higher comparing to the beginning of the year due to new leased premises. Non-current tangible assets amount to EUR 31.9 million which is an increase of EUR 2.0 million, or 6.87% compared to the beginning of the year due to equipping of new leased premises.

Long term financial assets mostly relate to the investment in related parties and given long-term cash loans. Long term financial assets amount to EUR 11.9 million and is almost at the level from the beginning of the year.

Long term receivables refer to long term receivables from customers and given merchandise loans to customers (merchandise loans are due receivables that are reprogrammed, and the payment has been agreed in the future periods). Long term receivables amount to EUR 5.7 million and have increased by 9.42% due to increased long-term receivables from one customer.

Current assets amount to EUR 487.6 million which is 27.94% higher compared to the beginning of the year.

Inventory amounts to EUR 95.8 million and has increased by EUR 10.3 million comparing to the beginning of the year, or 12.01%, which was most significantly affected by sales increase.

Total current receivables amount to EUR 361.4 million and are higher by EUR 75.7 million, or 26.51%, compared to the beginning of the year. Short term trade receivables, receivables from related parties and receivables from participating parties amounts to EUR 360.4 million and have increased by 26.39% compared to the beginning of the year mostly due to slower collection from hospitals.

Cash in bank and on hand amounts to EUR 30.1 million and record an increase by EUR 20.5 million comparing to the beginning of the year.

Long-term liabilities amount to EUR 11.2 million, out of which EUR 6.3 million relates to liabilities under operating leases (in accordance with IFRS 16 Leases), EUR 4.9 million to agreed payment instalments with suppliers, and EUR 44 thousand relates to finance lease liabilities.

Short term liabilities amount to EUR 425.7 million out of which the biggest part in amount of EUR 345.8 million relates to trade payables and liabilities to related parties and EUR 72.2 million to credit indebtedness toward banks and financial institutions (EUR 72.0 million short term credits and EUR 225 thousand financial lease).

Short term trade payables and liabilities to related parties are higher by EUR 52.1 million comparing to the beginning of the year, or by 17.75% and amounting EUR 345.8 million.

Medika's total credit indebtedness amounts to EUR 72.0 million, which is an increase of EUR 37.0 million compared to the beginning of the year for the purposes of current liquidity. The total amount of credit indebtedness as at 30 September 2025 relates to short-term borrowings.

Key events

In the first nine months of 2025, the pharmaceutical product market increased by 13.02% compared to the same period of the previous year.

Medika's sales increased by 17.64% compared to the same period of the previous year, resulting in an increase in the market share of 1.57 percentage points, and it is 39.84%.

Credit indebtedness increased by EUR 37.0 million compared to the beginning of the year for the liquidity purposes.

Expected future development of the Company

The Company will continue with its core business, distribution of medicinal products and medical devices and strongly develop operations with products that make the core business of the Company.

Treasury shares

As at 30 September 2025, the Company holds 1,240 treasury shares.

Subsidiaries and associates

The Company has 100% ownership in subsidiary Ljekarne Prima Pharmer.

At the meeting of the Supervisory Board, which was held on 7 November 2023, the Management Board received approval to conduct an abbreviated termination of Primus nekretnine d.o.o. without liquidation. During 2024, Primus nekretnine d.o.o. ceased operations.

Ljekarne Prima Pharme has an associate ZU Ljekarne Jagatić in which it holds 49% of ownership.

Related parties

The company with major voting rights, Auctor d.o.o. owns 48.04% of the Company and has 50.10% of shares with voting rights.

Pliva Hrvatska d.o.o., Zagreb owns 25.32% of the Company and has 26.41% of the voting rights. Given the share in the ownership and business transactions with the Company, Pliva Hrvatska has significant influence on the current operations of the Company.

Financial risks and exposure to price risk, credit risk, liquidity and cash flow risk

The most significant market risk for the Company is the long collection period for trade receivables, especially HZZO (Croatian State Health Insurance) related receivables. Therefore, a significant amount of working capital is not available, which strongly affects the cash flow of the Company and timely settlement of its liabilities.

As the receivables represent, directly or indirectly, amounts owed by state institutions, their collection should not be regarded as probable of default risk. This indirectly increases the need for additional funding, which means additional business costs.

Credit risk arises primarily from trade receivables. The risk is higher when dealing with privately owned pharmacies. Hospitals, on the other hand, have extended collection periods, but there is no risk of non-settlement.

A part of the Company's assets are interest-bearing assets, as a result of which its revenue and investing cash flows depend on fluctuations in market interest rates.

With the introduction of the euro as the official currency in the Republic of Croatia on 1 January 2023, the company's currency risk is significantly reduced.

The Company's interest rate risk arises from its short-term and long-term borrowings at variable rates. Variable-rate borrowings expose the Company to the interest-rate cash flow risk. Fixed-rate borrowings expose the Company to the interest-rate fair value risk.


Price risk arises from continuous decrease in the prices of prescription medicinal products on the HZZO list and administrative approach in determining the prices and margins of medicinal products. To lower this risk, the Company has focused on expanding the lines of products that are not limited by law in respect of the price of the product.

Regarding EU restriction measures, which refers to the consequences of exposure and the impact of the Russian invasion of Ukraine, Medika d.d. declares that it does not have a direct business relationship with entities from Russia or Ukraine, nor it is otherwise directly exposed to those entities in its business.

Nevertheless, the Company's Management Board estimates that a direct impact on the Company operations is possible due to the impact of the entire economy on global level, mainly due to the increase in the price of the energy products, both raw materials, interest rates and inflation that have increased further with the Russian invasion of Ukraine. Given the uncertain extent of the impact of the economy, the Company monitors developments and assesses the impact on business financial situation and cash flows.

³ **Medika** d.d.
ZAGREB, Capraška 1

Jasminko Herceg, dipl.oec.
President of the Management Board



Annex 1

ISSUER'S GENERAL DATA

Reporting period:

1.1.2025

to

30.9.2025

Year:

2025

Quarter:

3

Quarterly financial statements

Registration number (MB):

03209741

Issuer's home Member

State code:

HR

Entity's registration
number (MBS):

080027531

Personal identification
number (OIB):

94818858923

LEI:

7478000000R8ZVGJJO27

Institution
code:

1339

Name of the issuer: MEDIKA d.d.

Postcode and town:

10000

ZAGREB

Street and house number: CAPRAŠKA 1

E-mail address: medika.uprava@medika.hr

Web address: www.medika.hr

Number of employees
(end of the reporting

598

Consolidated report:

KN

(KN-not consolidated/KD-consolidated)

Audited:

RN

(RN-not audited/RD-audited)

Names of subsidiaries (according to IFRS):

Registered office:

MB:

Bookkeeping firm:

No

(Yes/No)

(name of the bookkeeping firm)

Contact person: INES BOSNAR ŠMITUC

(only name and surname of the contact person)

Telephone: 01/2412 551

E-mail address: medika.uprava@medika.hr

Audit firm:

(name of the audit firm)

Certified auditor:

(name and surname)

3 Medika d.d.
ZAGREB, Capraška 1

BALANCE SHEET
balance as at 30.09.2025

in EUR

Submitter: Medika d.d.

Item	ADP code	Last day of the preceding business year	At the reporting date of the current period
1	2	3	4
A) RECEIVABLES FOR SUBSCRIBED CAPITAL UNPAID	001	0	0
B) FIXED ASSETS (ADP 003+010+020+031+036)	002	55.858.516	63.876.080
I INTANGIBLE ASSETS (ADP 004 to 009)	003	8.969.210	14.308.534
1 Research and development	004	0	0
2 Concessions, patents, licences, trademarks, software and other rights	005	3.255.245	12.246.765
3 Goodwill	006	1.583.328	1.583.328
4 Advances for the purchase of intangible assets	007	4.086.519	466.198
5 Intangible assets in preparation	008	44.118	12.243
6 Other intangible assets	009	0	0
II TANGIBLE ASSETS (ADP 011 to 019)	010	29.824.515	31.873.887
1 Land	011	3.106.546	3.106.546
2 Buildings	012	12.658.376	12.303.456
3 Plant and equipment	013	3.774.307	4.612.584
4 Tools, working inventory and transportation assets	014	1.790.114	2.652.106
5 Biological assets	015	0	0
6 Advances for the purchase of tangible assets	016	605.123	655.246
7 Tangible assets in preparation	017	6.714.576	7.414.409
8 Other tangible assets	018	107.747	110.347
9 Investment property	019	1.067.726	1.019.193
III FIXED FINANCIAL ASSETS (ADP 021 to 030)	020	11.787.820	11.929.448
1 Investments in holdings (shares) of undertakings within the group	021	10.617.825	10.617.825
2 Investments in other securities of undertakings within the group	022	0	0
3 Loans, deposits, etc. to undertakings within the group	023	0	0
4. Investments in holdings (shares) of companies linked by virtue of participating interests	024	0	0
5 Investment in other securities of companies linked by virtue of participating interests	025	0	0
6 Loans, deposits etc. to companies linked by virtue of participating interests	026	0	0
7 Investments in securities	027	0	0
8 Loans, deposits, etc. given	028	1.169.995	1.311.623
9 Other investments accounted for using the equity method	029	0	0
10 Other fixed financial assets	030	0	0
IV RECEIVABLES (ADP 032 to 035)	031	5.173.834	5.661.074
1 Receivables from undertakings within the group	032	0	0
2 Receivables from companies linked by virtue of participating interests	033	0	0
3 Customer receivables	034	5.173.834	5.661.074
4 Other receivables	035	0	0
V DEFERRED TAX ASSETS	036	103.137	103.137
C) CURRENT ASSETS (ADP 038+046+053+063)	037	381.143.769	487.648.439
I INVENTORIES (ADP 039 to 045)	038	85.494.562	95.762.671
1 Raw materials and consumables	039	22.212	26.504
2 Work in progress	040	0	0
3 Finished goods	041	0	0
4 Merchandise	042	84.294.979	95.289.604
5 Advances for inventories	043	1.177.371	446.563
6 Fixed assets held for sale	044	0	0
7 Biological assets	045	0	0
II RECEIVABLES (ADP 047 to 052)	046	285.659.735	361.376.706

1 Receivables from undertakings within the group	047	17.748.254	13.066.370
2 Receivables from companies linked by virtue of participating interests	048	4.708.676	4.690.719
3 Customer receivables	049	262.663.831	342.603.331
4 Receivables from employees and members of the undertaking	050	892	416
5 Receivables from government and other institutions	051	121.627	107.713
6 Other receivables	052	416.455	908.157
III CURRENT FINANCIAL ASSETS (ADP 054 to 062)	053	375.199	428.348
1 Investments in holdings (shares) of undertakings within the group	054	0	0
2 Investments in other securities of undertakings within the group	055	0	0
3 Loans, deposits, etc. to undertakings within the group	056	0	0
4 Investments in holdings (shares) of companies linked by virtue of participating interests	057	0	0
5 Investment in other securities of companies linked by virtue of participating interests	058	0	0
6 Loans, deposits etc. to companies linked by virtue of participating interests	059	0	0
7 Investments in securities	060	0	0
8 Loans, deposits, etc. given	061	375.199	428.348
9 Other financial assets	062	0	0
IV CASH AT BANK AND IN HAND	063	9.614.273	30.080.714
D) PREPAID EXPENSES AND ACCRUED INCOME	064	126.674	311.194
E) TOTAL ASSETS (ADP 001+002+037+064)	065	437.128.959	551.835.713
OFF-BALANCE SHEET ITEMS	066	17.986.717	23.917.986
LIABILITIES			
A) CAPITAL AND RESERVES (ADP 068 to 070+076+077+083+086+089)	067	95.257.771	111.664.318
I INITIAL (SUBSCRIBED) CAPITAL	068	27.778.480	27.778.480
II CAPITAL RESERVES	069	-282.844	-282.844
III RESERVES FROM PROFIT (ADP 071+072-073+074+075)	070	11.067.694	11.067.694
1 Legal reserves	071	2.461.810	2.461.810
2 Reserves for treasury shares	072	6.478.463	6.478.463
3 Treasury shares and holdings (deductible item)	073	-2.081.712	-2.081.712
4 Statutory reserves	074	0	0
5 Other reserves	075	4.209.133	4.209.133
IV REVALUATION RESERVES	076	0	0
V FAIR VALUE RESERVES AND OTHER (ADP 078 to 082)	077	0	0
1 Financial assets at fair value through other comprehensive income (i.e. available for sale)	078	0	0
2 Cash flow hedge - effective portion	079	0	0
3 Hedge of a net investment in a foreign operation - effective portion	080	0	0
4 Other fair value reserves	081	0	0
5 Exchange differences arising from the translation of foreign operations (consolidation)	082	0	0
VI RETAINED PROFIT OR LOSS BROUGHT FORWARD (ADP 084-085)	083	41.439.674	56.883.508
1 Retained profit	084	41.439.674	56.883.508
2 Loss brought forward	085	0	0
VII PROFIT OR LOSS FOR THE BUSINESS YEAR (ADP 087-088)	086	15.254.767	16.217.480
1 Profit for the business year	087	15.254.767	16.217.480
2 Loss for the business year	088	0	0
VIII MINORITY (NON-CONTROLLING) INTEREST	089	0	0
B) PROVISIONS (ADP 091 to 096)	090	105.774	105.774
1 Provisions for pensions, termination benefits and similar obligations	091	105.774	105.774
2 Provisions for tax liabilities	092	0	0
3 Provisions for ongoing legal cases	093	0	0
4 Provisions for renewal of natural resources	094	0	0
5 Provisions for warranty obligations	095	0	0

6 Other provisions	096	0	0
C) LONG-TERM LIABILITIES (ADP 098 to 108)	097	5.346.536	11.247.208
1 Liabilities to undertakings within the group	098	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	099	0	0
3 Liabilities to companies linked by virtue of participating interests	100	0	0
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	101	0	0
5 Liabilities for loans, deposits etc.	102	0	0
6 Liabilities to banks and other financial institutions	103	186.133	44.379
7 Liabilities for advance payments	104	0	0
8 Liabilities to suppliers	105	4.238.199	4.887.952
9 Liabilities for securities	106	0	0
10 Other long-term liabilities	107	922.204	6.314.877
11 Deferred tax liability	108	0	0
D) SHORT-TERM LIABILITIES (ADP 110 to 123)	109	335.468.508	425.726.015
1 Liabilities to undertakings within the group	110	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	111	0	0
3 Liabilities to companies linked by virtue of participating interests	112	23.930.735	29.604.394
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	113	0	0
5 Liabilities for loans, deposits etc.	114	0	0
6 Liabilities to banks and other financial institutions	115	35.344.597	72.224.509
7 Liabilities for advance payments	116	392.230	37.728
8 Liabilities to suppliers	117	269.763.392	316.220.214
9 Liabilities for securities	118	0	0
10 Liabilities to employees	119	1.302.642	973.177
11 Taxes, contributions and similar liabilities	120	3.910.233	5.478.880
12 Liabilities arising from the share in the result	121	5.076	5.076
13 Liabilities arising from fixed assets held for sale	122	0	0
14 Other short-term liabilities	123	819.603	1.182.037
E) ACCRUALS AND DEFERRED INCOME	124	950.370	3.092.398
F) TOTAL – LIABILITIES (ADP 067+090+097+109+124)	125	437.128.959	551.835.713
G) OFF-BALANCE SHEET ITEMS	126	17.986.717	23.917.986

STATEMENT OF PROFIT OR LOSS
for the period 01.01.2025 to 30.09.2025

in EUR

Submitter: Medika d.d.

Item	ADP code	Same period of the previous year		Current period	
		Cumulative	Quarter	Cumulative	Quarter
1	2	3	4	5	6
I OPERATING INCOME (ADP 002 to 006)	001	599.008.370	202.468.572	687.501.788	234.805.927
1 Income from sales with undertakings within the group	002	47.216.778	15.583.467	49.774.391	16.794.445
2 Income from sales (outside group)	003	548.256.181	185.653.538	633.269.622	216.949.081
3 Income from the use of own products, goods and services	004	0	0	0	0
4 Other operating income with undertakings within the group	005	55.927	18.875	33.972	9.698
5 Other operating income (outside the group)	006	3.479.484	1.212.692	4.423.803	1.052.703
II OPERATING EXPENSES (ADP 08+009+013+017+018+019+022+029)	007	586.279.626	198.173.294	675.536.025	231.050.841
1 Changes in inventories of work in progress and finished goods	008	0	0	0	0
2 Material costs (ADP 010 to 012)	009	571.401.017	192.961.872	657.711.310	224.612.747
a) Costs of raw materials and consumables	010	1.391.654	426.772	1.390.420	471.715
b) Costs of goods sold	011	566.794.753	191.330.646	652.201.344	222.832.591
c) Other external costs	012	3.214.610	1.204.454	4.119.546	1.308.441
3 Staff costs (ADP 014 to 016)	013	8.836.068	3.053.749	10.092.996	3.544.420
a) Net salaries and wages	014	5.529.253	1.902.083	6.283.227	2.194.061
b) Tax and contributions from salary costs	015	2.157.894	752.743	2.512.311	893.216
c) Contributions on salaries	016	1.148.921	398.923	1.297.458	457.143
4 Depreciation	017	2.303.836	791.132	3.115.603	1.159.463
5 Other costs	018	3.550.694	1.206.009	3.944.257	1.181.847
6 Value adjustments (ADP 020+021)	019	188.011	160.532	671.859	552.364
a) fixed assets other than financial assets	020	0	0	0	0
b) current assets other than financial assets	021	188.011	160.532	671.859	552.364
7 Provisions (ADP 023 to 028)	022	0	0	0	0
a) Provisions for pensions, termination benefits and similar obligations	023	0	0	0	0
b) Provisions for tax liabilities	024	0	0	0	0
c) Provisions for ongoing legal cases	025	0	0	0	0
d) Provisions for renewal of natural resources	026	0	0	0	0
e) Provisions for warranty obligations	027	0	0	0	0
f) Other provisions	028	0	0	0	0
8 Other operating expenses	029	0	0	0	0
III FINANCIAL INCOME (ADP 031 to 040)	030	2.313.774	1.095.914	9.345.051	4.408.873
1 Income from investments in holdings (shares) of undertakings within the group	031	0	0	0	0
2 Income from investments in holdings (shares) of companies linked by virtue of participating interests	032	0	0	0	0
3 Income from other long-term financial investment and loans granted to undertakings within the group	033	0	0	0	0
4 Other interest income from operations with undertakings within the group	034	0	0	0	0
5 Exchange rate differences and other financial income from operations with undertakings within the group	035	0	0	0	0
6 Income from other long-term financial investments and loans	036	0	0	0	0
7 Other interest income	037	2.313.774	1.095.914	9.345.051	4.408.873
8 Exchange rate differences and other financial income	038	0	0	0	0
9 Unrealised gains (income) from financial assets	039	0	0	0	0
10 Other financial income	040	0	0	0	0
IV FINANCIAL EXPENSES (ADP 042 to 048)	041	1.324.359	618.957	1.358.206	508.788
1 Interest expenses and similar expenses with undertakings within the group	042	67.595	22.057	0	0
2 Exchange rate differences and other expenses from operations with undertakings within the group	043	0	0	0	0
3 Interest expenses and similar expenses	044	1.256.764	596.900	1.358.206	508.788
4 Exchange rate differences and other expenses	045	0	0	0	0
5 Unrealised losses (expenses) from financial assets	046	0	0	0	0
6 Value adjustments of financial assets (net)	047	0	0	0	0
7 Other financial expenses	048	0	0	0	0
V SHARE IN PROFIT FROM UNDERTAKINGS LINKED BY VIRTUE OF PARTICIPATING INTERESTS	049	0	0	0	0
VI SHARE IN PROFIT FROM JOINT VENTURES	050	0	0	0	0
VII SHARE IN LOSS OF COMPANIES LINKED BY VIRTUE OF PARTICIPATING INTEREST	051	0	0	0	0
VIII SHARE IN LOSS OF JOINT VENTURES	052	0	0	0	0
IX TOTAL INCOME (ADP 001+030+049 +050)	053	601.322.144	203.564.486	696.846.839	239.214.800
X TOTAL EXPENDITURE (ADP 007+041+051 + 052)	054	587.603.985	198.792.251	676.894.231	231.559.629
XI PRE-TAX PROFIT OR LOSS (ADP 053-054)	055	13.718.159	4.772.235	19.952.608	7.655.171
1 Pre-tax profit (ADP 053-054)	056	13.718.159	4.772.235	19.952.608	7.655.171

2 Pre-tax loss (ADP 054-053)	057	0	0	0	0
XII INCOME TAX	058	2,568,040	893,362	3,735,128	1,433,048
XIII PROFIT OR LOSS FOR THE PERIOD (ADP 055-059)	059	11,150,119	3,878,873	16,217,480	6,222,123
1 Profit for the period (ADP 055-059)	060	11,150,119	3,878,873	16,217,480	6,222,123
2 Loss for the period (ADP 059-055)	061	0	0	0	0
DISCONTINUED OPERATIONS (to be filled in by undertakings subject to IFRS only with discontinued operations)					
XIV PRE-TAX PROFIT OR LOSS OF DISCONTINUED OPERATIONS (ADP 063-064)	062	0	0	0	0
1 Pre-tax profit from discontinued operations	063	0	0	0	0
2 Pre-tax loss on discontinued operations	064	0	0	0	0
XV INCOME TAX OF DISCONTINUED OPERATIONS	065	0	0	0	0
1 Discontinued operations profit for the period (ADP 062-065)	066	0	0	0	0
2 Discontinued operations loss for the period (ADP 065-062)	067	0	0	0	0
TOTAL OPERATIONS (to be filled in only by undertakings subject to IFRS with discontinued operations)					
XVI PRE-TAX PROFIT OR LOSS (ADP 055-+062)	068	0	0	0	0
1 Pre-tax profit (ADP 068)	069	0	0	0	0
2 Pre-tax loss (ADP 068)	070	0	0	0	0
XVII INCOME TAX (ADP 058+065)	071	0	0	0	0
XVIII PROFIT OR LOSS FOR THE PERIOD (ADP 068-071)	072	0	0	0	0
1 Profit for the period (ADP 068-071)	073	0	0	0	0
2 Loss for the period (ADP 071-068)	074	0	0	0	0
APPENDIX to the P&L (to be filled in by undertakings that draw up consolidated annual financial statements)					
XIX PROFIT OR LOSS FOR THE PERIOD (ADP 076+077)	075	0	0	0	0
1 Attributable to owners of the parent	076	0	0	0	0
2 Attributable to minority (non-controlling) interest	077	0	0	0	0
STATEMENT OF OTHER COMPREHENSIVE INCOME (to be filled in by undertakings subject to IFRS)					
I PROFIT OR LOSS FOR THE PERIOD	078	11,150,119	3,878,873	16,217,480	6,222,123
II OTHER COMPREHENSIVE INCOME/LOSS BEFORE TAX (ADP 80+ 87)	079	0	0	0	0
III Items that will not be reclassified to profit or loss (ADP 081 to 085)	080	0	0	0	0
1 Changes in revaluation reserves of fixed tangible and intangible assets	081	0	0	0	0
2 Gains or losses from subsequent measurement of equity instruments at fair value through other comprehensive income	082	0	0	0	0
3 Fair value changes of financial liabilities at fair value through statement of profit or loss, attributable to changes in their credit risk	083	0	0	0	0
4 Actuarial gains/losses on the defined benefit obligation	084	0	0	0	0
5 Other items that will not be reclassified	085	0	0	0	0
6 Income tax relating to items that will not be reclassified	086	0	0	0	0
IV Items that may be reclassified to profit or loss (ADP 088 to 095)	087	0	0	0	0
1 Exchange rate differences from translation of foreign operations	088	0	0	0	0
2 Gains or losses from subsequent measurement of debt securities at fair value through other comprehensive income	089	0	0	0	0
3 Profit or loss arising from effective cash flow hedging	090	0	0	0	0
4 Profit or loss arising from effective hedge of a net investment in a foreign operation	091	0	0	0	0
5 Share in other comprehensive income/loss of companies linked by virtue of participating interests	092	0	0	0	0
6 Changes in fair value of the time value of option	093	0	0	0	0
7 Changes in fair value of forward elements of forward contracts	094	0	0	0	0
8 Other items that may be reclassified to profit or loss	095	0	0	0	0
9 Income tax relating to items that may be reclassified to profit or loss	096	0	0	0	0
V NET OTHER COMPREHENSIVE INCOME OR LOSS (ADP 080+087-086 - 096)	097	0	0	0	0
VI COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 078+097)	098	11,150,119	3,878,873	16,217,480	6,222,123
APPENDIX to the Statement on comprehensive income (to be filled in by undertakings that draw up consolidated statements)					
VI COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 100+101)	099	0	0	0	0
1 Attributable to owners of the parent	100	0	0	0	0
2 Attributable to minority (non-controlling) interest	101	0	0	0	0

STATEMENT OF CASH FLOWS - indirect method
for the period 01.01.2025 to 30.09.2025

in EUR

Submitter: Medika d.d.

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
Cash flow from operating activities			
1 Pre-tax profit	001	13.718.159	19.952.608
2 Adjustments (ADP 003 to 010):	002	2.404.255	-3.060.883
a) Depreciation	003	2.303.836	3.115.603
b) Gains and losses from sale and value adjustment of fixed tangible and intangible assets	004	1.589	-106.758
c) Gains and losses from sale and unrealised gains and losses and value adjustment of financial assets	005	188.011	671.859
d) Interest and dividend income	006	-2.313.774	-9.345.051
e) Interest expenses	007	1.256.764	1.358.206
f) Provisions	008	0	0
g) Exchange rate differences (unrealised)	009	1.666	4.066
h) Other adjustments for non-cash transactions and unrealised gains and losses	010	966.163	1.241.192
I Cash flow increase or decrease before changes in working capital (ADP 001+002)	011	16.122.414	16.891.725
3 Changes in the working capital (ADP 013 to 016)	012	-61.882.981	-33.712.239
a) Increase or decrease in short-term liabilities	013	10.186.461	55.008.126
b) Increase or decrease in short-term receivables	014	-63.331.455	-77.438.070
c) Increase or decrease in inventories	015	-8.737.987	-11.282.295
d) Other increase or decrease in working capital	016	0	0
II Cash from operations (ADP 011+012)	017	-45.760.567	-16.820.514
4 Interest paid	018	-1.050.677	-179.335
5 Income tax paid	019	-3.103.694	-2.782.294
A) NET CASH FLOW FROM OPERATING ACTIVITIES (ADP 017 to 019)	020	-49.914.938	-19.782.143
Cash flow from investment activities			
1 Cash receipts from sales of fixed tangible and intangible assets	021	19.798	133.799
2 Cash receipts from sales of financial instruments	022	0	0
3 Interest received	023	2.315.295	9.338.705
4 Dividends received	024	0	0
5 Cash receipts from repayment of loans and deposits	025	2.337.690.549	750.100
6 Other cash receipts from investment activities	026	0	0
III Total cash receipts from investment activities (ADP 021 to 026)	027	2.340.025.642	10.222.604
1 Cash payments for the purchase of fixed tangible and intangible assets	028	-4.783.006	-4.351.263
2 Cash payments for the acquisition of financial instruments	029	0	0
3 Cash payments for loans and deposits for the period	030	-2.318.508.697	-500.000
4 Acquisition of a subsidiary, net of cash acquired	031	0	0
5 Other cash payments from investment activities	032	0	0
IV Total cash payments from investment activities (ADP 028 to 032)	033	-2.323.291.703	-4.851.263
B) NET CASH FLOW FROM INVESTMENT ACTIVITIES (ADP 027 +033)	034	16.733.939	5.371.341
Cash flow from financing activities			
1 Cash receipts from the increase in initial (subscribed) capital	035	0	0
2 Cash receipts from the issue of equity financial instruments and debt financial instruments	036	0	0
3 Cash receipts from credit principals, loans and other borrowings	037	70.000.000	197.000.000
4 Other cash receipts from financing activities	038	0	0

V Total cash receipts from financing activities (ADP 035 to 038)	039	70.000.000	197.000.000
1 Cash payments for the repayment of credit principals, loans and other borrowings and debt financial instruments	040	-36.891.048	-159.982.000
2 Cash payments for dividends	041	-5.790.800	0
3 Cash payments for finance lease	042	-377.140	-261.842
4 Cash payments for the redemption of treasury shares and decrease in initial (subscribed) capital	043	0	0
5 Other cash payments from financing activities	044	-426.722	-1.878.915
VI Total cash payments from financing activities (ADP 040 to 044)	045	-43.485.710	-162.122.757
C) NET CASH FLOW FROM FINANCING ACTIVITIES (ADP 039 +045)	046	26.514.290	34.877.243
1 Unrealised exchange rate differences in respect of cash and cash equivalents	047	0	0
D) NET INCREASE OR DECREASE IN CASH FLOWS (ADP 020+034+046+047)	048	-6.666.709	20.466.441
E) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	049	9.023.670	9.614.273
F) CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD(ADP 048+049)	050	2.356.961	30.080.714

"FINANCIAL STATEMENT NOTES**(are compiled for quarterly reporting periods)****Issuer: MEDIKA d.d.****OIB: 94818858923****Reporting period: 01.01.2025 - 30.09.2025****Notes to the financial statements for quarterly periods include:**

a) an explanation of business events that are significant for understanding the changes in the statement of financial position and business results for the reporting quarter of the issuer compared to the last business year, ie publish information related to these events and update relevant information published in the last annual financial report (paragraphs 15 to 15C IAS 34 - Financial Reporting for Periods during the Year).

Financial statements of Medika d.d. have been prepared in accordance with International Financial Reporting Standards adopted by the European Union (IFRS). Financial statements of Medika d.d. are made using the historical cost method, unless otherwise stated.

The preparation of financial statements in conformity with International Financial Reporting Standards as adopted by the European Union (IFRS) requires the use of certain critical accounting estimates.

On 30.09.2025, compared to the beginning of the year, Medika d.d. increased credit indebtedness by EUR 37 million.

Significant business events and transactions in the observed period, which are important for understanding the changes in the Statement of Financial Position and Business Results are explained in pdf document - Interim Management Report for I-IX 2025 Medika, which was published simultaneously on this website Medika dd www.medika.hr, on the website of the Zagreb Stock Exchange d.d. and submitted to the Official Register of Prescribed Information at the Croatian Financial Services Supervisory Agency.

b) information where access to the most recent annual financial statements is provided, in order to understand the information disclosed in the notes to the financial statements prepared for the reporting quarter.

The notes to the financial statements are attached to the audited annual financial statements of Medika d.d. The audited annual financial statements for 2024 are available on the website of Medika d.d. www.medika.hr, on the website of the Zagreb Stock Exchange d.d. and were submitted to the Official Register of Prescribed Information at the Croatian Financial Services Supervisory Agency.

c) a statement that the same accounting policies are applied in preparing the financial statements for the quarterly period as in the most recent annual financial statements or, if those accounting policies have changed, a description of the nature and effect of the change (paragraph 16A (a) of IAS 34 Financial Reporting for periods during the year).

The financial statements were prepared on the basis of the same accounting policies, presentations and calculation methods as well as they were in the annual financial statements on 31 December 2024.

d) an explanation of the business results in the event that the issuer performs an activity of a seasonal nature (paragraphs 37 and 38 of IAS 34 - Financial Reporting for Periods during the Year).

Medika d.d. does not perform activities of a seasonal nature.

e) other disclosures prescribed by IAS 34 - Financial Reporting for periods during the year

Non-current intangible assets amount to EUR 14.3 million which is by 59.53% higher comparing to the beginning of the year due to new leased premise. Non-current tangible assets amount to EUR 31.9 million which is an increase of EUR 2.0 million, or 6.87% compared to the beginning of the year due to equipping new leased premise.

Short-term and long-term receivables from customers, related companies and participating companies amount to EUR 366.0 million and recorded an increase of EUR 75.7 million or 26.09% compared to the beginning of the year.

Reclassification:

AOP 119 Liabilities to employees include short-term provisions.

Assets with the right of use are stated within long-term intangible assets by type of assets, while lease liabilities are stated within other long-term and short-term liabilities.

Interest payable on loans is stated within other short-term liabilities.

f) in addition to the above information, the following information shall be disclosed in the notes to the financial statements for the quarterly period:

1. name, registered office of the undertaking (address), legal form of the undertaking, country of establishment, registration number of the entity, personal identification number and, if applicable, that the undertaking is in liquidation, bankruptcy, summary winding up or extraordinary administration

Name of the issuer: Medika d.d.,

Headquarters: Capraška 1, 10000 Zagreb

Legal form: joint stock company

Country of establishment: Republic of Croatia

MBS: 080027531

OIB: 94818858923

2. adopted accounting policies (only an indication of whether there has been a change compared to the previous period)

Medika d.d. during the reporting period did not change its accounting policies compared to the previous year.

3. the total amount of any financial liabilities, guarantees or contingencies not included in the balance sheet, as well as an indication of the nature and form of any actual insurance provided; all liabilities relating to the pensions of an entrepreneur within a group or company related to a participating interest are disclosed separately.

For a certain part of liabilities to suppliers and loans (which are shown in the balance sheet) Medika d.d. issued guarantees from banks or debentures as collateral.

Liabilities from provisions for pensions are presented in the balance sheet in accordance with IAS-19.

4. the amount and nature of individual items of income or expenditure of exceptional size or occurrence.

Medika d.d. in the reporting period 01.01.-30.09.2025 has generated net sales revenues in the amount of EUR 683.0 million and are 14% higher compared to the same period of the previous year (in the period 01.01.-30.09.2024 amount to EUR 595.5 million).

5. amounts owed by the entrepreneur and maturing after more than five years, as well as the total debts of the entrepreneur covered by valuable insurance provided by the entrepreneur, with an indication of the type and form of insurance.

Medika d.d. on 30.09.2025 have liabilities over 5 years and are almost entirely related to operating lease liabilities in the amount of EUR 3.4 million.

Long-term tangible assets with a net book value as of 30 September 2025 are pledged as collateral for the loan amounts to EUR 15.1 million.

6. average number of employees during the current period.

Average number of employees during the current period 01.01.-30.09.2025. amounts 592 employees (during the period 01.01.-30.09.2024. the average number of employees was 581 employees).

7. if the entrepreneur in the business year in accordance with the regulations capitalized the cost of salaries in part or in full, information on the amount of total employee costs during the year broken down into the amount directly charged to the period and the amount capitalized in the value of assets during the period. for each part, it shall state separately the total amount of net salaries and the amount of taxes, contributions from salaries and contributions to salaries.

Medika d.d. did not capitalize the cost of wages during the reporting period.

8. if deferred tax provisions, deferred tax balances at the end of the business year and movements of these balances during the business year are recognized in the balance sheet.

Deferred tax assets on 30.09.2025. amounted to EUR 103 thousand.

9. the name and registered office of each undertaking in which the undertaking, alone or through a person acting in his own name but on behalf of the undertaking, holds a participating share in the capital, showing the amount of capital held, the amount of total capital and reserves, business years of the undertaking concerned, for which the annual financial statements have been adopted; information on capital and reserves and profit or loss may be omitted if the undertaking in question does not publish its balance sheet and is not under the control of another undertaking.

Medika d.d. has 100% stake in Ljekarne Prima Pharme which holds 49% stake in the associated company ZU Ljekarna Jagatić.

At the meeting of the Supervisory Board which was held on 7 November 2023, the Management Board received approval to conduct an abbreviated termination of Primus nekretnine d.o.o. without liquidation. During 2024, Primus nekretnine d.o.o. ceased operations.

10. number and nominal value, or if there is no nominal value, the book value of shares or stakes subscribed during the business year within the authorized capital.

No new shares are subscribed during the business year. Share capital as at 30.09.2025. is EUR 27.8 million and is divided into 30,194 shares. The nominal value of one share is EUR 920.

11. the existence of any certificates of participation, convertible debentures, guarantees, options or similar securities or rights, indicating their number and the rights they grant.

Medika d.d. has no certificates of participation, convertible debentures, guarantees, options or similar securities or rights.

12. name, registered office and legal form of each undertaking in which the undertaking has unlimited liability.

Medika d.d. has no stake in unlimited liability companies.

13. the name and registered office of the undertaking which draws up the quarterly consolidated financial statements of the largest group of undertakings in which the undertaking participates as a controlled member of the group.

Not applicable.

14. the name and registered office of the undertaking which draws up the quarterly consolidated financial statements of the smallest group of undertakings in which the undertaking participates as a controlled member and which is also included in the group of undertakings referred to in point 13.

Not applicable.

15. the place where copies of the quarterly consolidated financial statements referred to in points 13 and 14 can be obtained, provided that they are available.

Not applicable.

16. the nature and business purpose of undertakings' arrangements not included in the balance sheet and the financial impact of those arrangements on the undertaking, provided that the risks or rewards of such arrangements are material and to the extent necessary to disclose such risks or rewards.

Medika d.d. has no material arrangements with companies that are not included in the financial statements as of 30 September 2025.

17. the nature and financial impact of significant events that occurred after the balance sheet date and were not reflected in the income statement or balance sheet.

Medika d.d. has no significant events that occurred after the balance sheet date and were not reflected in the income statement or loss or balance sheet.

Regarding EU restriction measures, which refers to the consequences of exposure and the impact of the Russian invasion of Ukraine, Company declares that it does not have a direct business relationship with entities from Russia or Ukraine, nor is it otherwise directly exposed to those entities in its business.

Nevertheless, the Company's management estimates that an indirect impact on the Company's operations is possible due to the impact on the entire economy on global level, mainly due to the increase in the price of energy products, both raw materials, interest rates and inflation that have increased further with the Russian invasion of Ukraine. Given the uncertain extent of the impact on the economy, the Company monitors developments and assesses the impact on business, financial situation and cash flows.

Zagreb, 28 October 2025

Pursuant to the articles 462 to 471 of the Capital market Law (Official Gazette 65/18, 17/20, 83/21, 151/22 and 85/24) President of the Management Board Jasminko Herceg provides

STATEMENT OF LIABILITY FOR PREPARING FINANCIAL STATEMENTS OF ISSUER

Unaudited unconsolidated and consolidated financial statements of Medika d.d. have been prepared pursuant to the International Financial Reporting Standards (IFRS) and Croatian Accounting Law.

Unaudited unconsolidated and consolidated financial statements for the period 01 January to 30 September 2025 present true and fair view of assets and liabilities, financial position, profit or loss of the Company and the Group.

The interim management report for the unaudited financial statements for the period 01 January to 30 September 2025 presents fair presentation of development and results of the operations and position of the Company and the Group with description of significant risks and uncertainties for the Company and the Group.

³ **Medika** d.d.
ZAGREB, Capraška 1

Jasminko Herceg
President of the Management Board